KEGG   DRUG: Lifileucel
Entry
D12833                      Drug                                   
Name
Lifileucel (USAN/INN);
Amtagvi (TN)
Product
AMTAGVI (Iovance Biotherapeutics)
Remark
ATC code: L01XL11
Product: D12833<US>
Efficacy
Antineoplastic
  Disease
Melanoma (BRAF V600 mutation positive) [DS:H00038]
  Type
Cellular therapy product
Comment
Treatment of metastatic melanoma
Human culture expanded activated tumor-derived autologous T cells for cell-based immunotherapy.
Target
CD4 [HSA:920] [KO:K06454]
CD8 [HSA:925 926] [KO:K06458 K06459]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04640  Hematopoietic cell lineage
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL11 Lifileucel
      D12833  Lifileucel (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD4
     D12833  Lifileucel (USAN/INN) <US>
    CD8
     D12833  Lifileucel (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12833
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12833
Other DBs
CAS: 2306267-74-1
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system